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Characterisation of PALB2 tumours through whole-exome
and whole-transcriptomic analyses
Pei Sze Ng1,2, Jia Wern Pan1, Muhammad Mamduh Ahmad Zabidi1, Pathmanathan Rajadurai3, Cheng Har Yip3, Oscar M. Reuda 4,
Alison M. Dunning5, Antonis C. Antoniou6, Douglas F. Easton 5,6, Carlos Caldas 4,7,8, Suet-Feung Chin 4 and Soo Hwang Teo 1,2✉
Rare protein-truncating variants (PTVs) in PALB2 confer increased risk to breast cancer, but relatively few studies have reported the
characteristics of tumours with PALB2 PTVs. In this study, we describe molecular characteristics of tumours with either germline or
somatic alterations in PALB2. DNA from fresh frozen tumour tissues and matched peripheral blood lymphocytes for 560 breast
cancer patients was subjected for whole-exome sequencing (WES), and RNA from tumour tissues was subjected to RNA sequencing
(RNA-seq). We found six cases with germline and three with somatic protein-truncating variants in PALB2. The characteristics of
tumours in patients with PALB2 PTVs were similar to those with BRCA1 and BRCA2 PTVs, having significantly more somatic
alterations, and a high proportion of the mutational signature and genomic scar scores characteristic of deficiencies in homologous
recombination (HR), compared to tumours arising in non-carriers. Unlike tumours arising in patients with BRCA1 and BRCA2 PTVs,
PALB2 tumours did not have high prevalence of TP53 somatic alterations or an enriched immune microenvironment. In summary,
PALB2 tumours show the homologous recombination deficiencies characteristic of BRCA1 and BRCA2 tumours, and highlight the
potential clinical relevance of PALB2 mutational status in guiding therapeutic choices.
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INTRODUCTION
PALB2 [Partner and Localizer of BRCA2] plays a vital role in the
maintenance of genome integrity and repair of DNA double-
strand breaks via homologous recombination (HR) pathway, by
localising BRCA2 to the sites of DNA damage and serving as a
linker between BRCA1 and BRCA21,2. Biallelic (homozygous)
germline protein-truncating variants (PTVs) in PALB2 result in
Fanconi anaemia3, whereas monoallelic (heterozygous) PTVs
predispose individuals to breast, ovarian and pancreatic cancers4,5.
In addition to the use of germline testing for PALB2 for
management of risk to breast and other cancers, there is
increasing interest in exploring the potential impact of PALB2
variants on response to PARP inhibitors. Two recent studies using
formalin-fixed tissues show that a significant proportion of the
tumours arising in PALB2 loss of function germline carriers have a
loss of the second allele and biallelic loss of PALB2 results in the
acquisition of genomic characteristics consistent with deficiency in
double-strand DNA break repair6,7. However, in part because of
the rarity of germline carriers, there has hitherto been no reports
of genomic analyses from fresh frozen tumour samples.
In this study, we report the genomic and transcriptomic
characteristics of fresh frozen and formalin-fixed paraffin-
embedded tumours with PALB2 alterations, in comparison to the
tumours with BRCA1 or BRCA2 alterations and non-carriers.
RESULTS
Characteristics of tumours arising in PALB2 carriers
Of the 560 breast tumours with available sequencing data,
subsequent genomic and transcriptomic profiling was conducted
only for samples that passed quality checks [WES, n= 546; sWGS,
n= 533; RNA-seq, n= 527]. Germline sequencing identified six
individuals with PALB2 PTVs, 10 with BRCA1 PTVs and 11 with
BRCA2 PTVs. Whole-exome sequencing (WES) data of tumour DNA
identified somatic PTVs in PALB2 in a further 3 tumours, BRCA1 in
six tumours and BRCA2 in three tumours (Fig. 1a and Supplemen-
tary Table 1). One tumour from an individual with a germline
PALB2 PTV also had a somatic PALB2 PTV (likely biallelic
inactivation via somatic inactivation of the second allele). For all
subsequent analyses, tumours with germline or somatic PTVs were
considered together. Tumours with germline and somatic
missense variants in PALB2 (n= 7), BRCA1 (n= 2) and BRCA2 (n
= 11) were excluded.
Of the nine tumours with germline or somatic PALB2 PTVs, three
were triple negative, one was ER-positive/PR-negative/HER2-
positive, three were ER-positive/PR-positive/HER2-negative, and
two were ER-positive/PR-negative/HER2 negative. For the tumours
where data were available (n= 8), all the tumours were either
grade 2 or 3 (Fig. 1a). Tumours with PTVs in BRCA1 were more
likely to be negative for the oestrogen receptor and progesterone
receptor by IHC (14/16 both ER- and PR-), and those with BRCA2
PTV were more likely to be positive for these receptors (12/14 ER
+, 9/14 PR+). Using RNA-seq analysis, we did not observe any
enrichment of any subtype in tumours with PALB2 germline or
somatic alterations. This is in contrast with BRCA1 tumours which
were strongly enriched for ‘basal’ and ‘IntClust 10’ subtype8, and
BRCA2 tumours which were slightly enriched for Luminal B
subtype (Fig. 1a and Supplementary Fig. 1).
Three (33%) of 9 PALB2 tumours had either loss of PALB2 wild-
type allele (two tumours) or somatic inactivation of the second
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allele (one tumour) (Fig. 1a and Supplementary Table 2). This rate
was lower when compared with 44% of tumours with biallelic
inactivation of BRCA1 (7/16) and 50% of tumours with biallelic
inactivation of BRCA2 (7/14) (Fig. 1, Supplementary Tables 1 and 2).
Overall, tumours with germline alterations in PALB2 and BRCA1
had significantly reduced gene expression of the respective genes
when compared to tumours without alterations, whereas there
was no statistically significant difference in expression of these
genes in tumours with somatic mutations. In contrast, BRCA2
tumours with somatic mutations had a significantly lower gene
expression levels compared to expression of tumours arising in
non-carriers (Fig. 1b). Tumours with biallelic inactivation of PALB2
and BRCA2, and monoallelic BRCA1 tumours had a significantly
lower expression of the respective genes when compared to
tumours with no alterations (non-carriers) (Fig. 1c).
We compared the expression of genes in the ER pathway for
PALB2 tumours with that of BRCA1 and BRCA2 tumours. Tumours
with biallelic and monoallelic inactivation of BRCA1 had lower
expression of genes regulated by the estrogen receptor (Fig. 2a),
and this was particularly striking for genes that are positively
regulated by the estrogen receptor (Fig. 2b). Tumours with
biallelic, but not monoallelic inactivation of PALB2, had similar
lower expression of the genes regulated by the estrogen receptor
(Fig. 2a, b). By contrast, there was no difference in expression of
these genes in tumours with either biallelic or monoallelic
inactivation of BRCA2, nor in genes negatively regulated by the
estrogen receptor (Fig. 2c) or in the progesterone pathway (Fig.
2d).
Given that BRCA1 tumours are more likely to be ER- negative,
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Fig. 1 Characteristics of tumours with germline and somatic alterations in PALB2, BRCA1 and BRCA2. a Phenobar showing the allelic status,
pathology and molecular characteristics of tumours. b Comparison of gene expression between tumours with germline and somatic PTV
alterations, and tumour with no alterations (non-carriers). c Comparison of gene expression between tumours with biallelic inactivation,
monoallelic inactivation and tumour with no alterations (non-carriers). Boxplots represent medians (centre line) and interquartile range, and
whiskers represent the maximum and minimum values within 1.5 times the interquartile range from the edge of the box. Each data point
represents an individual sample. P values: Comparison of each category vs non-carrier. ***p < 0.001; **p < 0.01; *p < 0.05; Mann–Whitney U test.
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receptor pathway by ER subtype. Although the sample size was
small, this exploratory analysis showed that the expression of
genes positively regulated by estrogen receptor was numerically
lower in PALB2 and BRCA1 tumours in both ER-positive and ER-
negative disease (Fig. 2f), but there was no difference in
expression of genes negatively regulated by estrogen receptor
(Fig. 2g) or in the progesterone pathway (Fig. 2h).
Next, we conducted an exploratory analysis to determine the
key differentially expressed genes in PALB2, BRCA1 and BRCA2
tumours compared to tumour in non-carriers. We found 709, 3297
and 1760 genes that were significantly differentially expressed
between PALB2, BRCA1 and BRCA2 tumours compared to non-
carriers. Intriguingly, a large proportion of the differentially
expressed genes identified in PALB2 tumours (98.2%, 696/709)
overlapped with the differentially expressed genes identified in
BRCA1 and BRCA2 tumours. Gene Ontology (GO) functional
enrichment analysis demonstrated that the upregulated differen-
tially expressed genes for PALB2 tumours were enriched in the
molecular function and cellular component terms associated with
RNA and protein binding. Pathway enrichment analysis showed
that the top results were enriched in metabolism of RNA,
transcription, translation and metabolism of protein which was
highly similar with what were observed in BRCA1 and BRCA2
tumours (Supplementary Fig. 2).
Mutational profiles of PALB2 tumours
Using WES analyses, we characterised the prevalence of driver
gene mutations in tumours with germline and somatic alterations
in PALB2, BRCA1 and BRCA2. TP53 somatic mutations were found in
11% of PALB2 tumours (1/9), compared to 63% of BRCA1 tumours
(10/16), and 43% of BRCA2 tumours (6/14) (Fig. 3). PIK3CA somatic
mutations were found in 22% of PALB2 tumours (2/9), compared
to 25% of BRCA1 tumours (4/16), and 14% of BRCA2 tumours (2/
14). There were no other commonly mutated driver genes found
in PALB2 tumours (Fig. 3).
Using WES data, we determined the total number of somatic
mutations [small insertion–deletions (indels) and single nucleotide
variations (SNVs)] for each tumour sample. Tumours with biallelic
inactivation of PALB2, BRCA1 and BRCA2 had a significantly higher
number of somatic mutations compared to tumours of non-
carriers (median 125, 146 and 214 respectively compared to 46 in
non-carriers, p= 0.0364, 0.0009 and 0.0137, respectively). How-
ever, the number of somatic mutations was not significantly
different in tumours with monoallelic inactivation of PALB2, BRCA1
or BRCA2 compared to tumours of non-carriers [median 74, 42 and
68 respectively compared to 46 in non-carriers, p= 0.2026, 0.5362
and 0.4258, respectively, Fig. 4a].
Next, we determined the proportion of the major mutational
signatures in the tumour samples (Supplementary Figure 3).
Tumours with biallelic inactivation of PALB2, BRCA1 or BRCA2 had a
higher proportion of mutational signature 3 [mean 48.9%, 44.4%
and 39.5% respectively compared to 8.2% in non-carriers, p=
0.0114, 0.0007 and 0.0064, respectively; Fig. 4b]. However, the
proportion of mutational signature 3 was not significantly
different in tumours with monoallelic inactivation of PALB2, or
BRCA1 compared to tumours of non-carriers [mean 18.8% and
15.1% respectively compared to 8.2% in non-carriers, p= 0.3881
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Fig. 2 ER and PR pathway analysis, stratified by allelic status (a–d) and hormone status (e–h). a GO intracellular ER signature pathway. b GO
positive regulatory ER pathway. c GO negative regulatory ER pathway. d GO response to progesterone pathway (only samples with available
RNA-seq data were included in this analysis). e GO intracellular ER signature pathway. f GO positive regulatory ER pathway. g GO negative
regulatory ER pathway. h GO response to progesterone pathway. Boxplots represent medians (centre line) and interquartile range, and
whiskers represent the maximum and minimum values within 1.5 times the interquartile range from the edge of the box. Each data point
represents an individual sample. P values: Comparison of each category vs non-carrier. ***p < 0.001; **p < 0.01; *p < 0.05; Mann–Whitney U test
(bootstrap analysis was applied).
P.S. Ng et al.
3
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)    46 
monoallelic inactivation of BRCA2 was marginally higher than that
in non-carriers [mean of 30.6% compared to 8.2% in non-carriers,
p= 0.0491].
We examined the other features of HR deficiency including
genomic loss of heterozygosity (LOH), telomeric allelic imbalance
(TAI) and large-scale state transition (LST). Tumours with biallelic
inactivation of PALB2, BRCA1 and BRCA2 had a significantly higher
scores of LOH compared to tumours of non-carriers (median 14, 19
and 13 respectively compared to 6 in non-carriers, p= 0.0171,
0.0002 and 0.0015, respectively). Tumours with biallelic inactiva-
tion of PALB2, BRCA1 and BRCA2 also had a significantly higher TAI
scores compared to tumours of non-carriers (median 27, 26 and 19
respectively compared to 9 in non-carriers, p= 0.0164, 0.0002 and
0.0002 respectively). Tumours with biallelic inactivation of PALB2,
BRCA1 and BRCA2 had a significantly higher large-scale transition
scores compared to tumours of non-carriers (median 22, 26 and 21
respectively compared to 7 in non-carriers, p= 0.0200, 0.0002 and
0.0003, respectively). Overall, the HRD scores (HRD-sum) was
higher for tumours with biallelic inactivation of PALB2, BRCA1 and
BRCA2 compared to non-carriers. However, none of these
measures were significantly different in tumours with monoallelic
inactivation of PALB2, BRCA1 or BRCA2 compared to tumours of
non-carriers (Fig. 4c).
Immune profiles of PALB2 tumours
We examined the immune tumour microenvironment through
bioinformatics analysis of immune-related genes, and found that
tumours with monoallelic inactivation of BRCA1 had higher CD8
positive T-cell cytotoxicity (as measured by cytolytic (CYT) index;
Fig. 5a) and a higher immune infiltrate (as measured by ESTIMATE
score; Fig. 5b). Tumours with biallelic inactivation of PALB2 had
higher immune infiltrate (Fig. 5b), but all other tumours did not
have increased immune profiles (Fig. 5a, b).
We retrieved and performed immunohistochemistry (IHC) on
the corresponding formalin-fixed paraffin-embedded tumour
samples and found that BRCA1 tumours had higher levels of
CD3, CD4, CD8 and PD-L1 positive staining compared to non-
carriers, but there were no significant differences in the
percentage of TILs or PD-L1 expression of BRCA2 and PALB2
tumours compared to non-carriers (Fig. 5c).
Survival analyses
Given the association between mutation status and immune
profiles, we explored the association between mutation status and
breast cancer survival. We found that women with PALB2 PTVs had
poorer survival compared to BRCA carriers and non-carriers, but
the result was not statistically significant (Supplementary Fig. 4).
DISCUSSION
This study describes the characteristics of tumours that arise from
PALB2 carriers based on the integration of genomics and transcrip-
tomics analysis in fresh-frozen tumour samples. Despite the relatively
small sample size, our analyses show that tumours with biallelic
inactivation in PALB2 are similar to that with biallelic inactivation in
BRCA1 or BRCA2 in that they are of high grade, had higher mutational
load9,10 and appear to display mutational signatures9–13 and
chromosomal instabilities that are characteristic of loss of the HR
pathway14,15. Intriguingly, we found that tumours with biallelic
inactivation in PALB2 and BRCA1, appear to have downregulation of
genes regulated in the estrogen receptor pathway and that the
majority of the differentially expressed genes are similarly
Fig. 3 The oncoplot shows all the somatic mutations identified in PALB2 tumours in comparison to BRCA1 and BRCA2 tumours in the top
20 mutated genes commonly associated with breast cancer (with prevalence indicated as reported previously by 18). The lower bottom
panel represented somatic alterations in PALB2 tumours identified in other additional genes. Each column represented a sample.
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dysregulated in BRCA1 and BRCA2 tumours. However, unlike BRCA1
tumours, PALB2 tumours do not appear to display an enriched
immune microenvironment. Taken together, these data suggest that
biallelic loss of PALB2 may result in tumour features that are broadly
similar to that of biallelic loss of BRCA1, adding further weight to the
body of evidence that carriers of PALB2 alterations should be
considered for therapies, which have been approved for use in
germline carriers of BRCA1 and BRCA2, such as PARP inhibitors14.
100a.                                                                    b.       
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Fig. 4 Comparison of mutational profiles of tumours (with integrated germline and somatic alterations) that arise from mutation carriers
of PALB2, BRCA1 and BRCA2 and non-carriers, stratified by allelic status of tumours. a Total number of somatic alterations (single
nucleotide variants (SNVs)) and indels identified in tumours with PTVs. b The stacked bar plot shows the proportion of major mutational
signature in aggregate for each category. The horizontal grey dashed line indicates the proportion of mutational signature 3 in tumours that
arise from non-carriers as reference for comparison. Only samples with at least 15 SNVs were included in this analysis. c Comparison of
genomic scar scores for tumours with PTVs and tumours without any alterations (non-carrier group). All samples were included in this analysis
except those with no Sequenza files due to unavailability of either WES germline or tumour data. Boxplots represent medians (centre line) and
interquartile range, and whiskers represent the maximum and minimum values within 1.5 times the interquartile range from the edge of the
box. Each data point represents an individual sample. P values: Comparison of each category vs non-carrier. ***p < 0.001; **p < 0.01; *p < 0.05;
Mann–Whitney U test (a, c); Chi-square test (b).
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Fig. 5 Comparison of immune profiles of tumours (with integrated germline and somatic alterations) that arise from mutation carriers of
PALB2, BRCA1 and BRCA2 and non-carriers. a Cytolytic index (CYT), as measure of CD8+ T cell cytotoxicity. b ESTIMATE score, as measure of
lymphocytic infiltration. c Distribution of TILs and PD-L1 expression. Only samples with IHC images for analysis were included in this analysis.
d Representative images of H&E and IHC for CD3, CD4 and CD8 where image analysis was performed. Boxplots represent medians (centre line)
and interquartile range, and whiskers represent the maximum and minimum values within 1.5 times the interquartile range from the edge of
the box. Each data point represents an individual sample. P values: Comparison of each category vs non-carrier. **p < 0.01; *p < 0.05;
Mann–Whitney U test (CD3, CD4 and CD8); Chi-square test (PD-L1 positive score).
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Our results are consistent with previous studies in tumours with
biallelic inactivation of PALB2 using targeted sequencing or whole-
exome analysis of paraffin-embedded tissue. Notably, the use of
WES has enabled us to characterise genome-wide mutational load,
which adds to the previous analyses involving targeted sequen-
cing of ~500 genes7. In addition, the analysis of tumours with
PALB2, BRCA1 and BRCA2 alterations collected at the same centre
and analysed at the same time with the same platform, confirms
previous WES analyses conducted on paraffin-embedded material
where the TCGA dataset analysed from frozen material on a
different platform was used as a comparator6. Taken together, the
results show that biallelic inactivation of PALB2 is associated with
the higher mutation load, the higher proportion of mutational
signature 3, or the higher genomic scar scores indicative of
genomic instability.
However, there are some differences between our results and
previous published studies. The prevalence of biallelic loss of
PALB2 at 50% of germline carriers is slightly lower than the 67%
reported in previous studies6,7. Whilst this may be due to chance
because of the small dataset, it warrants further investigation as
the tumour features appear to be associated with biallelic loss of
PALB2 and is not statistically significant in tumours with
monoallelic loss of PALB2. In addition, the frequency of somatic
TP53 mutations in PALB2 tumours (1/9, 11%) was lower than that
reported previously using deeper targeted sequencing
approaches [21% (5/24) and 40% (6/15)] of PALB2 tumours,
respectively6,7. However, the prevalence of PIK3CA somatic
mutations in PALB2 tumours (2/9, 22%) was consistent with that
previously reported (29%)6.
Finally, this study explored the immune microenvironment in
PALB2 tumours. Whilst we found an enrichment in immune genes,
as determined using the ESTIMATE immune profiles, this was not
found when we examined CYT scores, nor immunohistochemical
staining with CD3, CD4, CD8 or PD-L1. These results suggest that
there may be unique characteristics of BRCA1-associated tumour
that modulates their enriched immune microenvironment, that is
distinct from the shared functions that BRCA1 shares with PALB2
and BRCA2 in genomic instability16.
This study has several limitations. Despite being a unique study
with fresh frozen tumour genomic analyses, the number of
samples available for analyses was small. Hence some differences
in tumour characteristics between PALB2 carriers and non-carriers
may have been missed, and the frequencies of specific
characteristics could only be crudely estimated. In particular, the
lower frequency of immune infiltration and relatively high
frequency of PIK3CA mutations need to be confirmed in larger
studies. Further studies using larger sample sizes should define
the distribution of genomic features more precisely, and hence
provide better understanding of the role of PALB2 germline and
somatic variants in the oncogenesis.
In conclusion, this study has demonstrated similarities and
highlighted potential differences between tumours arising in
PALB2 PTV carriers with that of BRCA1 and BRCA2 carriers. In
particular, these results confirm that biallelic loss of PALB2 results
in tumour characteristics, which may be sensitive to therapies
targeting the HR pathway in ways that are similar to biallelic loss
of BRCA1 and BRCA2.
METHODS
Study subjects and biospecimen acquisition
Breast tumour and peripheral blood specimen were obtained from 656
patients diagnosed with breast cancer who underwent surgical resection in
Subang Jaya Medical Centre between September 2012 and March 2017.
The study participants were women with breast cancer who were recruited
in the Malaysian Breast Cancer Genetic (MyBrCa) study17. Representative
fresh tumour tissues excised from the primary tumour were collected at
surgery, immediately frozen and stored in liquid nitrogen. Recruitment and
genetic studies have been approved by the Ethics Committee of Subang
Jaya Medical Centre [reference no: 201208.1] and written informed consent
was given by each participant.
During cryo-sectioning, two 8-µm frozen sections were collected from
each tissue (at the beginning and end of sectioning), placed on the same
slide (Polysine slides, Thermo Scientific, UK) and thereafter stained with
Hematoxylin & Eosin (H&E) stain [Hematoxylin Harris (Product code:
351945 S, BDH, USA); Eosin Y solution (Product code: 1098441000, Merck,
Germany)]. Subsequently, ten 30-µm sections were taken in an alternate
manner from each tumour, placed into two sets of tubes pre-filled with the
respective lysis buffer (supplied with the DNeasy Blood and Tissue Kit and
miRNeasy Kit (Qiagen, Crawley, UK)) and kept frozen in −80 °C for nucleic
acid extractions at later time. The stained H&E slides were reviewed under
a light microscope to determine the tumour content (by taking the
average of both sections). Only cases with average tumour content ≥30%
and with sufficient quality and quantity of nucleic acid were selected and
subjected for sequencing as described previously. Additional cases were
excluded from this study for the following reasons: no corresponding
germline samples, those that withdrew consent from the study and those
with rare histology subtypes that were not suitable to be included in this
study (mucinous, malignant phylloides).
Nucleic acid isolation, quantification, and quality assessment
DNA from blood samples was extracted using the Maxwell 16 Blood DNA
Purification Kit with the Maxwell 16 Instrument (Promega, Madison, WI,
USA) according to standard protocol. DNA and RNA were extracted and
purified from ten 30-µm sections each from fresh frozen tumours using the
DNeasy Blood and Tissue Kit and the miRNeasy Kit (Qiagen, Crawley, UK)
on the QIAcube (Qiagen) according to the manufacturer’s instructions. The
purity and quantity of nucleic acids were quantified with a NanoDrop ND-
2000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA)
and the integrity of random DNA samples was assessed by agarose gel
electrophoresis. Purified DNA were further quantified by flourometry using
the Qubit dsDNA HS [high sensitivity] Assay kit with Qubit 2.0 fluorometer
(Thermo Scientific). RNA integrity was assessed using the Agilent 2100
Bioanalyser Nanochip (Agilent Technologies, Wokingham, UK). For DNA
samples, only tumour samples with a concentration above 20 ng/µL were
included for WES, whilst for RNA, only samples with concentration of
10 ng/µL with RNA integrity number of 7 and above were included for
whole-transcriptomic sequencing, respectively.
Sequencing of germline and tumour samples
Germline DNA, tumour DNA and RNA were subjected for library
preparation and sequenced as described previously18. Briefly, for the
WES, DNA libraries were generated from 50 ng of genomic DNA using the
Nextera Rapid Capture Exome kit and subjected to paired end 75 base pair
sequencing on the Hi-Seq 4000 platform (Illumina, San Diego, USA). In
addition, 4 nM pools of DNA libraries was subjected to shallow whole-
genome sequencing (sWGS). Exome capture was performed in pools of 3
and subjected to paired end 75 sequencing on a HISEQ4000 platform
(Illumina, San Diego, USA). For RNA-seq, RNA libraries were prepared from
550 ng of total RNA using the TruSeq Stranded Total RNA HT kit with Ribo-
Zero Gold (Illumina, San Diego, USA) and subjected to paired end 75 base
pair sequencing on a Hi-Seq 4000 (Illumina, San Diego, USA).
Bioinformatics analysis
Analysis of sequencing data was performed as described previously18.
Briefly, for WES, sequenced reads were aligned to the human reference
genome GRCh37 using BWA-MEM19. Local realignment, duplicate removal
and base quality recalibration were performed using the Genome Analysis
Toolkit (GATK, v3.1.1)20. Somatic SNVs were detected using GATK3
Mutect220, whilst small insertions and deletions (indels) were called by
Strelka221. RNA-seq, reads were mapped to the hs37d5 human genome
and the ENSEMBLE GrCh37 release 87 human transcriptome using the
STAR aligner (v.2.5.3a)22. Variant calling for RNA-seq data was also
conducted using the GATK Best Practices workflow for RNA-seq.
Mutational signatures
Only samples with at least 15 SNVs were used to determine the mutational
signatures. The weights of previously reported breast cancer mutational
signatures from using COSMIC matrices, (Signatures 1, 2, 13, 3, 8, 6, 15, 20,
26, 5, 17, 18 and 30) were determined using deconstructSigs23.
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HR deficiency scores
The following measures of HR deficiency were determined as described
previously: (1) LOH, (2) LST and, (3) TAI24–26. Allele-specific copy number
(ASCN) profiles on paired normal-tumour BAM files were determined using
Sequenza27 and used to calculate the individual measure scores and HRD-
sum scores using the scarHRD R package28.
Molecular classification based on gene expression data
Classification into breast cancer subgroups was performed using PAM5029
and Integrative Clusters (IntClust)30.
Cytolytic index (CYT) and ESTIMATE score
CYT index (which is a measure of CD8+ T-cell cytotoxicity) was obtained by
quantifying the transcript levels of 2 genes, granzyme A (GZMA) and
perforin 1 (PRF1)31. ESTIMATE (v. 1.0.13)32 gives a measure of immune cell
infiltration by performing ssGSEA based on inferred immune signature. The
ESTIMATE immune score was obtained by using ‘estimate’ R package.
Evaluation of tumour infiltrating lymphocytes (TILs) and PD-
L1
Formalin-fixed paraffin-embedded (FFPE) blocks for 456 patients with
sequencing data were sectioned and stained for anti-CD3 (clone 2GV6,
predilute; Ventana Medical Systems), anti-CD4 (clone SD35, predilute;
Ventana Medical Systems), anti-CD8 (clone SD57, predilute; Ventana
Medical Systems) and anti-PD-L1 (clone SP263, predilute; Ventana Medical
Systems) using an automated immunostainer (Ventana BenchMark ULTRA;
Ventana Medical Systems, Tucson, AZ). Stained slides were digitised using
an Aperio AT2 whole slide scanner. CD3, CD4, and CD8 staining were
quantified using the Aperio Positive Pixel digital pathology tool (v9
algorithm at 0.16 colour saturation). PD-L1 expression was determined
using the Combined Positive Score system (0: no stain (negative); 1: ≥1%
positive tumour cells staining).
Determination of locus-specific loss of PALB2, BRCA1 and
BRCA2 wild-type allele (locus-specific LOH)
Locus-specific LOH of germline PALB2, BRCA1 and BRCA2 mutation in the
tumour was determined using two methods: 1. ASCN calls14 and 2. Allele
frequency comparisons33. Briefly, ASCN calls of the genomic region
containing the PALB2, BRCA1 and BRCA2 germline mutation were
determined by Sequenza as reported previously14,27 and a tumour sample
is considered to have LOH if the variant allele frequency in the DNA of the
tumour sample was >20% than that in the corresponding germline DNA33.
In cases where there was difference in both calls, a third method, to
determine the genome-wide copy number data using QDNAseq where
sWGS data were used as input to substantiate the LOH34.
Differential gene expression and functional enrichment
analysis
Gene expression was analysed with the limma package, an R-based open-
source software designed to analyse transcriptomic data for differential
expression, as previously described18. GO enrichment analysis, Kyoto
Encyclopaedia of Genes and Genomes pathway enrichment analysis and
Reactome pathway analysis were performed using the Database for
Annotation, Visualisation and Integration Discovery (DAVID, http://david.
abcc.ncifcrf.gov/)35. The p value was adjusted by Bonferroni correction.
Statistical analysis
The Mann–Whitney U test and the Chi-square test were performed for
comparisons of variables between mutation categories. P < 0.05 was
considered statistically significant and all tests were two-sided. Statistical
analyses were performed using R v3.6.1. Bootstrap analysis was performed
using R to account for the difference in sample size. In brief, 30 non-carrier
controls were randomly selected for comparison with each category of
mutation carriers. The process was iterated 1000× and two tailed p value
was calculated with the Mann–Whitney U test for each iteration. The
median of all iterations was determined and used as the final corrected
p value.
Survival analysis
Overall survival data were obtained for each patient as previously
described18. The Cox proportional hazard model was built using “coxph’
function from the survival package adjusting for covariates and plotted
using the ‘ggforest” function from survminer R package. Adjusted survival
curves were calculated based on the Cox model and plotted using
“ggadjustedcurves” function.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data generated and analysed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.1420716536. Sequencing data (WES,
RNA-seq and sWGS bam files) are available on the European Genome-phenome
Archive under the study accession number https://identifiers.org/ega.study:
EGAS0000100451837. Access to controlled patient data will require the approval of
the MyBrCa Tumour Genomics Data Access Committee upon request to the
corresponding author at genetics@cancerresearch.my. Characteristics of tumours
with germline and somatic PTV identified in PALB2, BRCA1 and BRCA2 carriers and
differentially expressed genes (DEGs) are shared openly as part of the data record36.
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